TMCnet News
Law Offices of Frank R. Cruz Encourages Erasca, Inc. (ERAS) Shareholders To Inquire About Securities Fraud Class ActionThe Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"). Erasca investors have until August 10, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR ERASCA, INC. (ERAS) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com. What Happened? On April 27, 2026, before market hours, Erasca disclosed that it had received a letter from legal counsel for Revolution Medicines, Inc. ("RevMed") alleging that Erasca's drug candidate, ERAS-0015, infringes a RevMed patent and is connected to alleged trade secret misappropriation. RevMed also claimed that Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures" and demanded Erasca cease making "deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236." On this news, Erasca's stock price fell $2.34, or 10.9%, to close at $19.15 per share on April 27, 2026, thereby injuring investors. That same day, after market hours, Erasca reported preliminary Phase 1 clinical data from ERAS-0015, revealing that a patient had died approximately one month after starting ERAS-0015. On this news, Erasca's stock price fell $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) ERAS-0015's preclinical data was based on improper comparisons to RevMed and placed Erasca at risk of violating patent and trade secret protections; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260617807536/en/ |
